Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply
Year: 2021
Type: letter
Source: The Lancet Oncology
Authors: Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Lisa Zimmer, Claudia Trojaniello, Oliver Klein, Camille L Gerard, Olivier Michielin, Andrew Haydon, Paolo A Ascierto, Matteo S Carlino, Celeste Lebbe, Paul Lorigan, Douglas B Johnson, Shahneen Sandhu, Serigne N Lo, Alexander M Menzies, Georgina V Long
Institutions: The University of Sydney, Westmead Hospital, Melanoma Institute Australia, The Netherlands Cancer Institute, Memorial Sloan Kettering Cancer Center, Vanderbilt University Medical Center, National Health Service, The Christie NHS Foundation Trust, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, University Hospital Zurich, Essen University Hospital, University of Duisburg-Essen, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Olivia Newton-John Cancer Research Institute, Centre Hospitalier Universitaire Vaudois, The Alfred Hospital, Monash University, University of Manchester, Peter MacCallum Cancer Centre, Royal North Shore Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3192409202